Corporate Development

Since our founding, Geron has focused on strong science and the pursuit of R&D excellence to discover and develop innovative, first-in-class therapies for the treatment of cancer as evidenced through the collaborative development of our first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

As part of our value creation strategy, Geron is interested in potential acquisitions of new oncology products, programs or companies with innovative science behind potentially transformative medicines that will enable strategic growth of our pipeline. To contact our Corporate Development team, please send an e-mail to corpdev@geron.com.